Cagrilintide

Cagrilintide, a long-acting amylin analogue, promotes significant body weight reduction as monotherapy, achieving an average 11.8% loss over 68 weeks compared to 2.3% with placebo in phase 3 trials for adults with obesity or overweight.¹ It reduces appetite, enhances satiety, slows gastric emptying, and improves glycemic control, with greater effects in combination with semaglutide (CagriSema), yielding up to 20.4% weight loss, reduced waist circumference, and better physical functioning.²,³,⁴ These outcomes support its investigational role in obesity management, potentially addressing related metabolic complications like hyperglycemia.⁵,⁶

The most common side effects of cagrilintide are gastrointestinal disturbances, including mild to moderate nausea (affecting up to 47% of patients), constipation (21%), vomiting (8%), diarrhea or loose stools (7%), dyspepsia (4%), and abdominal discomfort or bloating, which are typically dose-dependent, transient, and most prominent during initial titration but often resolve with time, slower dose escalation, hydration, fiber intake, or physical activity.⁷,⁸ Injection site reactions occur frequently (up to 43%), along with less common effects like tiredness (20%), headache (7%), and allergic reactions (10%).⁸ Serious adverse events are rare (2-7% incidence, similar to comparators), with isolated reports of acute cholelithiasis, pancreatitis (not dose-dependent), and anti-drug antibodies (46-73% by week 26), though no new safety signals emerged over 68 weeks.⁸,⁹ Key safety considerations include avoiding use in patients with severe gastrointestinal conditions like gastroparesis, history of pancreatitis, pregnancy, or breastfeeding due to lack of data and potential exacerbation of symptoms.⁷,⁹ Discontinuation rates due to adverse effects are low (around 1-10%), and monitoring for persistent symptoms is advised.⁷,⁸

Cagrilintide is a long-acting amylin analog engineered to mimic the function of endogenous amylin, a hormone naturally co-secreted with insulin by pancreatic beta cells⁷,¹⁰. The active ingredient binds to amylin and calcitonin receptors—specifically AMY1R and AMY3R—primarily in the brain's satiety centers, including the area postrema, nucleus of the solitary tract, and lateral parabrachial nucleus¹¹. Through this receptor activation, cagrilintide enhances satiety signaling, reduces hunger, slows gastric emptying to prolong postprandial fullness, and suppresses glucagon secretion to support glucose homeostasis⁷,¹⁰. Molecular modifications to the amylin backbone extend cagrilintide's half-life substantially compared to native amylin, permitting once-weekly subcutaneous dosing in clinical practice⁷. When combined with semaglutide—a GLP-1 receptor agonist—cagrilintide produces additive appetite-suppressing effects through complementary pathways, targeting both the amylin and incretin networks for enhanced metabolic control in obesity and type II diabetes⁶,¹².